Barclays maintains DexCom at Overweight, raises price target to $120 from $115

What happened

Barclays maintained its Overweight rating on DexCom, which means it expects the stock to outperform, and raised its price target to $120 from $115, a 4.3% increase. The new target implies 50.1% upside from the October 29 close of $79.93.

Confirmed

Global impact / market context

A higher price target from a major broker signals that its analysts expect more upside in DexCom shares than before. Because Barclays kept its Overweight rating, the change suggests greater confidence in the company's prospects rather than a shift in view.

Analyst inference

Other recent analyst notes on DexCom carry targets between $93 and $115, so Barclays' $120 target sits above that range. This places Barclays among the more optimistic voices on the stock, which could draw investor attention to DexCom.

Analyst inference

What to watch

1. Barclays raised its target to $120 while keeping an Overweight rating, and the target implies 50.1% upside from the October 29 close of $79.93. Confirmed
2. Watch whether other analysts follow Barclays by lifting their own DexCom price targets, since the four most recent notes currently range from $93 to $115. Proposed
3. Track DexCom's share price against the $120 target; sustained gains toward it would suggest investors are accepting Barclays' more optimistic view of the stock's value. Analyst inference

Evidence

• Original source link unavailable